Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘UPLIFT' Study of TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for the Treatment of Major Depressive Disorder (MDD) - Marketscreener.com
Submitted by Anonymous (not verified) on Thu, 03/16/2023 - 11:01
